HC Wainwright & Co. Maintains Buy on Sutro Biopharma, Raises Price Target to $50

Benzinga Newsdesk www.benzinga.com Positive 86.3%

Neg 0% Neu 0% Pos 86.3%

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and raises the price target from $28 to $50.